NASDAQ Capital Marke • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD
DURECT Corporation (DRRX) has a consensus analyst rating of Buy, based on 13 analysts covering the stock. Of those, 8 recommend buying, 5 recommend holding, and 0 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
